Intellia NTLA-2001

Recruiting
99 years or below
All
Phase N/A
10 participants needed
1 Location

Brief description of study

To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, MI, arrhythmia, or stroke), compared to placebo Composite endpoint comprising Cardiovascular related mortality and frequency and timing of Cardiovascular events (urgent Heart Failure visits and hospitalizations due to Heart Failure, Myocardial Infraction, arrhythmia, or stroke) - Change from baseline to Month 18 in serum TTR - Change from baseline to Month 18 in KCCQ-OS score - Change from baseline to Month 18 in NT-proBNP - Cardiovascular related mortality, All-cause mortality - Frequency of CV events (urgent Heart Failure visits and hospitalizations due to Heart Failure, Myocardial Infarction, arrhythmia, or stroke)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 02 Jul 2025. Study ID: 23-1674

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center